25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...
NEW YORK, Aug. 29 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...
Plaintiff claims suffered damages in Korean Air Lines price fixing conspiracy SEATTLE, Aug. 10 /PRNewswire/ -- Seattle-based law firm Hagens...
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight...
Company Cites Continuing Progress on Clinical and Preclinical Programs NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc...
NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company primarily focused...
NEW YORK, June 25 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the...
NEW YORK, May 24 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drugs for the treatment of...
History of Atiprimod Appears in Genetic Engineering & Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals...
Independent German Based Equity Research Firm Maintains Buy Rating and $2.00 per share price target NEW YORK, April 24 /PRNewswire-FirstCall/...
Initiates Coverage with Market Outperform Rating and a price target of $3.00 per share NEW YORK, April 24 /PRNewswire-FirstCall/ -- Callisto...
Company Cites Progress with Clinical and Preclinical Programs NEW YORK, April 16 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex:...
Announces Positive Data in Animal Models of Ulcerative Colitis NEW YORK, April 5 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex:...
NEW YORK, March 12 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約